Stocks · News reference

HC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price Target

Oct 6, 2026, 10:18 AMBenzinga Newsdesk

HC Wainwright & Co. analyst Mitchell S. Kapoor upgrades Crescent Biopharma (NASDAQ:CBIO) from Neutral to Buy and announces $36 price target.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Oct 6, 2026, 10:18 AM
Checked: Oct 6, 2026, 10:18 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 15, 2026, 8:31 PMBenzinga Newsdesk
Crescent Biopharma Says Global Phase 1/2 APOLLO Trial Of CR-002, a PD-L1-Targeted ADC, On Track To Commence Dosing This Quarter; Initial Data Expected In H2 2027; Phase 1/2 Trial Of CR-003 (SKB105), An ITGB6-Targeted ADC, Ongoing In China; Initial Data Expected In Q1 2027
CBIO
SEC EDGAROct 15, 2026, 8:26 PMSEC EDGAR
8-K filing — CRESCENT BIOPHARMA, INC. (CBIO)
Filed: 2026-10-15 AccNo: 0001628280-26-066006 Size: 157 KB Item 8.01: Other Events
CBIO
BenzingaOct 15, 2026, 8:16 PMBenzinga Newsdesk
Crescent Biopharma Says Initial Data From Phase 1/2 CR-001 Trial On Track For Q1 2027; Sees Potential Phase 3 Start In Early 2028
CBIO